he has been instrumental in high-stakes litigation, including serving on the trial team representing children affected by in utero exposure to Depakote. She managed the firm’s Depakote docket, helping secure significant verdicts of $38 million and $15 million for affected families. She has also taken on major corporations, including Johnson & Johnson, Janssen, Merck, Boston Scientific, and GlaxoSmithKline. In recognition of her leadership, she was appointed by Judge Claire Cecchi to the Plaintiffs’ Steering Committee in the national Proton Pump Inhibitor litigation.
Most recently, Sejal represented a woman who was sexually assaulted by an Uber driver in a case tried in the Western District of North Carolina as part of a larger multidistrict litigation (MDL). With Judge Charles R. Breyer presiding, the case marked the second trial in the MDL and the first selected by Uber for trial purposes, ultimately resulting in a verdict in favor of the plaintiff.
In addition to her courtroom work, Sejal is a highly sought-after public speaker. She has presented at numerous national conferences, including the American Association for Justice, the MDL Judicial Summit, Texas Women Rainmakers, and Mass Torts Made Perfect. Her speaking engagements focus on pharmaceutical litigation, strategies for navigating the mass tort arena, and best practices for litigating complex pharmaceutical cases.